ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Oncternal Therapeutics's annualized net income for the quarter that ended in Dec. 2023 was $-36.66 Mil. Oncternal Therapeutics's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $33.52 Mil. Therefore, Oncternal Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 was -109.34%.
The historical rank and industry rank for Oncternal Therapeutics's ROE % or its related term are showing as below:
ONCT'
s ROE % Range Over the Past 10 Years
Min: -276.44 Med: -112.03 Max: -27.07
Current: -87.46
During the past 13 years, Oncternal Therapeutics's highest ROE % was -27.07%. The lowest was -276.44%. And the median was -112.03%.
ONCT's ROE % is ranked worse than 71.32% of 1360
companies
in the Biotechnology industry
Industry Median: -44.08
vs ONCT: -87.46
Oncternal Therapeutics ROE % Historical Data
The historical data trend for Oncternal Therapeutics's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncternal Therapeutics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncternal Therapeutics ROE % Distribution
For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's ROE % distribution charts can be found below:
* The bar in red indicates where Oncternal Therapeutics's ROE % falls into.
Oncternal Therapeutics ROE % Calculation
Oncternal Therapeutics's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2023) net income data.
ROE % is displayed in the 30-year financial page.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Oncternal Therapeutics ROE % Related Terms
Thank you for viewing the detailed overview of Oncternal Therapeutics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncternal Therapeutics (Oncternal Therapeutics) Business Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONCT has been successfully added to your 